ONecifts. The purpose of this study was to investigate the blologle elcacy and pharmacokineties of different doses of recom • bleat hirudin administered In single or repeated subcutaneous hgjeetion` In healthy volunteers.
39393. Plasma clearance was between 1 .5 and 1 .7 milmin per kg. The subcutaneous administration of 0 .3 and 0.5 mg recombinant hirudin three times a day for 3 days or two times a day for 6 days prolonged the activated partial thromboplastin time by 1 .71 to 1.69 and 1.78 to 1.92 times baseline levels, respectively, with the prefnjectlon values maintained in the hypocoagulable range . No prolongation of bleeding time was measured at peak plasma hirudin levels. Because thrombin and prothrombln times are not able to reflect high or low CGP 39393 concentrations, respectively, neither test is suitable for monitoring administration of this drug .
Co,wlusiwrs . CGP 39393 appears to be well tolerated in volunteers, even after repeated doses. The activated partial thromboplastin time test seem to be well suited to monitor the anticoagulant effect of recombinant hirudin because the dose effect is linear up to 0.5 mg/kg of subcutaneous CGP 39393 . The prolongation or activated partial thromboplastin time after sub• cutaneous injection of CGP 39393 shows a plateau lasting for 3 h . Further studies are now required to determine the dose that wilt provide the best antithrombotic effect and the lowest bleeding tendency in arterial or venous thrombosis indications . (j Am Coll Carrdol 1993; 22 :1080-8) inalls, except for the lack of a sulfato group on tyrosine 63
(1,2). Evaluation of rug) 39393 in various experimental models has demonstrated its anticoagulant, antiplatelet and antithrombotic properties . In vitro in human plasma and ex vivo after ascending intravenous or subcutaneous doses in rats, the dose-response curve exhibits linearity over a range greater than that observed for standard, unfractionated heparin (3) . The activated partial thromboplastin time prolongation persists for approximately I h after intravenous administration (0.3 mg/kg body weight) and for 2 h after subcutaneous administration (3 .0 mg/kg) . In nephrectomized rats, the intravenous duration of the anticoagulant action is prolonged to at least 4 h (4). In the shunt thrombosis model in the rat ;5), CGP 39393 can completely inhibit thrombus formation ; intravenous doses of 0.3 mg/kg and subcutaneous doses of 1 mg/kg reduce thrombus weight by 50% (3) . The antithrombotic effect correlates almost linearly with the 0735-1G97/931$6 .00 anticoagulant effect measured by activated partial thromboplastin time, so that full antithrombotic efficacy is achieved at, for example, a 3 .5-to 4-fold prolongation of the activated partial thromboplastin time after subcutaneous administration (4) . Heparin exhibits less linearity in this correlation . In the rat model of venous thrombosis (systemic hypercoagulability induced by intravenous thromboplastin C with inferior vena cava ligation), CGP 39393 has a median infective dose of 0 .01 mg/kg intravenously and 0 .45 mg/kg subcutaneously (3, 4) . These results are in line with those obtained with another recombinant hirudin used in a cardiopulmonary bypass model (6) .
The role of thrombin in platelet-mediated thrombosis has been demonstrated in several species, including the baboon (7) , the dog (8), the rabbit (9), the pig (10, 11) and the hamster (12) . Recombinant hirudin reduced platelet-mediated thrombus formation in deep arterial injuries in pigs ; the antithrombotic activity correlated with the prolongation of the activated partial thromboplastin time but not the thrombin time (13) . A similar conclusion was reached for recombinant hirudin in a hamster platelet-rich mural thrombosis model (14) .
Sufficient amounts of CGP 39393 are now available, and a series of studies were carried out to investigate and evaluate the biologic efficacy of different doses of subcutaneous CGP 39393 and to characterize the pharmacokinetic profile of the drug administered in single or repeated subcutaneous injections . That COP 39393 is well tolerated in volunteers, even after repeated doses, is being reported (15) .
Methods
Blood sampling . Blood for activated partial thromboplastin time, prothrombin time, thrombin time, thrombin chromogenic assay and recombinant hirudin assay was collected in tubes containing sodium citrate before and 30, 60, 90,120, 150 min and 3, 4, 5, 6, 8 and 24 h after injection . Blood for platelet count was collected in a tube containing ethylenediamine tetraacetic acid . Activated partial thromboplastin time . This test was performed in duplicate in trisodium citrated plasma (1 :9 ratio) with either an automated KC-4 or KC-10 coagulometer (Amelung Lemgo) working within a preset range of values (0 to 180 s) . The reagent Pathromtin (Behringwerke AG) was used in all centers as a source of phospholipids . The normal range is 28 to 40 s . Thrombin time. To obtain different sensitivities for thrombin time response, bovine thrombin was used at two concentrations (3 and 6 IU/ml) ; 0.1 ml of platelet-poor plasma and 0 .1 ml of diethylbarbiturate acetate buffer solution were incubated for I min at 37°C, and 0 .1 ml of thrombin solution was added . Commercial test thrombin (Behringwerke AG) and the automated KC-4 or KC-10 coagulometer were used . Normal values are 14 to 21 and 8 to 13 s for the lower and higher thrombin concentrations, respectively .
Prothrombin time . The addition of tissue extract and an excess of calcium to plasma initiates clottit . Commercial tissue extract was added to the citrated plas'aa, and the clotting time was recorded .
Thrombin chromogenic P;say. CGF 393G3 activity was measured within 4 h of blood samplinr, according to a modification of the method of Spannagl Ft al . (16) . Briefly, I ml of buffer containing 0 .3 IU of thrombin (Behringwerke AG), 5 .0 kallikrein inhibitor units/mml of aprotinin (Bayer AG) and 100 ng/nil of protamine chloride were added to 50 JA of sample (probe or standard) . This was incubated at 25°C for 2 min, and then 100 µl of Chroraozym TH (1 .9 mmol/liter) (Boehringer) was added . The change in absorbance was measured at 405 nm .
COP 39393 was added to immunocontrol Plasma Normal (Immuno AG) to obtain various concentrations of CGP 39393 standard (e .g ., 0, 50, 100, 200, 300, 400 and 500 ng/ml) . The standard curve .vas linear (between 0 and 500 ng/ml) . Samples with higher -oncentrations of CGP 39393 standard (e .g ., 1,000, 2 .000 and 3,000 ng/ml) had to be diluted . Control samples were obtained from the same test subject before the first recombinant hirudin administration (time 0) . All measurements were performed in duplicate on an EPOS photometer . Results are expressed in nmol/liter (0 .1 mg of CGP 39393 equals 14 .36 nmol) .
Plasma levels of CGP 39393. A double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) developed at Ciba-Geigy Ltd . measures free COP 39393 concentrations (17) . A first monoclonal antibody fixed on wells recognizes an epitope of CGP 39393, and a second biotin-covered antibody bound to another site of CGP 39393 produced1 a color when in the presence of a sufficient amount of enzyme and a chromogenic substrate . The intensity of the color is proportional to the concentration of CGP 39393 in the sample . In plasma, the limit of quantitation and the limit of detection are 1 . Protection of human subjects . The study protocols were approved by the Ethical Committee of each participating centers (see Appendix) . Written informed consent was obtained from each volunteer before entry into the study .
Statistical analysis and pharmacokinetic calculations. All tests were performed in duplicate . Areas under the plasma concentration-time curve were calculated according to the linear trapezoidal rule . Elimination half-life was calculated by the adjustment of a double-exponential function to the appropriate phases of the log-linear plasma concentration profile (20) .
Trial drug . Recombinant desulfato-hirudin (COP 39393) was supplied by Ciba-Geigy Ltd. It was produced and purified in collaboration with Gen Therapeutica Vertriebs GmbH & Co . The compound has the sequence of hirudin 
Results

Biakgic t>
y of a single dose of sabcute Moos CGP 39393 In healthy vdantee rs. A total of 184 healthy volunteers not previously exposed to hirudin received two single subcutaneous doses of 0 .1 mglkg of CGP 39393 injected I month apart . The activated partial thromboplastin time was prolonged from a mean ± SD of 37.2 ± 6.2 s before to 50.4 ± 9.2 s 2 h after the first injection and from 37,1 ± 3 .9 s to 51 .1 ± 7.2 s I month later. None of the volunteers -it any time reported an allergic reaction . >siologLc ethcacy of different doses of subcutaneous CGP 303 in healthy vohtMeers . The biologic efficacy and tolerability of different dose levels of CGP 39393 were investi . gated in 23 healthy, nonatopic volunteers previously never exposed to hirudin Each subject received two different single dose levels of COP 39393 separated by 2 to 34 days . The first group of four volunteers received 0 .1 mg/kg of CGP 39393 . Volunteers in subsequent groups of four could start with the next higher dose (0. only after results of the lower dose were known . Volunteers were followed up for 24 h after each subcutaneous injection but could be discharged earlier from the clinical pharmacology unit provided that the activated partial thromboplastin time had returned to within 20% of the baseline vahie .
After subcutaneous injection, CGP 39393 is rapidly absorbed : at 30 min after dosing, the median prolongation of the activated partial thromboplastin time was dose proportional (Table 1 ) . Mean activated partial thromboplastin time was prolonged in a dose-related manner (Fig . I) . The maximal effect of activated partial thromboplastin time was maintained until approximately 3 to 4 h after dosing, after which activated partial thromboplastin time levels gradually declined to near baseline . The mean levels by 8 h after dosing were still slightly prolonged for doses ?0.3 mg/kg (Table I) . Although the effect on activated partial thromboplastin time at higher doses of recombinant hirudin was maintained slightly longer, the mean activated partial thromboplastin time values had returned by 24 h to approximately baseline values for all dose levels tested .
A dose-related prolongation of the thrombin time up to 0.4 mg/kg of CGP 39393 was apparent when the test was performed with 6 IU of thrombin/ml ( Changes in the plasma concentration of CGP 39393 (twostep thrombin chromogenic assay method) were dose related, with peak levels within 30 to 120 min after injection at all dose levels (Table 1) . High plasma concentrations were maintained until approximately 3 h after dosing up to 0.4 mg/kg and 4 .8 h after higher dosing, with a return to near-baseline values by 24 h . As assessed by the immunologic method, the concentrations of CGP 39393 were on average 1 .7 times those obtained with the functional method .
Single subcutaneous injections of recombinant hirudin displayed dose-proportional, linear kinetic effects (immunologic assay) ( ELISA) (Cmax) and the area under the plasnw concentrationtime curve (AUC) for doses 0.110.3 and 0 .210 .1 mg/kg of CGP 39393 was 25% to 46%, about twice as large as intrasubjeet variation (10% to 25%) . Dose-normalized Crnax and AUC were independent of dose ; therefore the pharmacokinetic effects of CGP 39393 were linear. There was a clear relation between the inhibition of coagulation, measured as activated partial thromboplastin time, and plasma concentrations of CGP 39393 (linear leastsquares regression analysis ; r = 0.8399, n = 334) (Fig . 2) . The activated partial thromboplastin time extends in a linear manner over the whole range of hirudin plasma levels, whereas the thrombin time does not (Fig . 2 ) . *CGP 39393 ; relative molecular mass 6,964 ;1 mg corresponds to 143 nmol . AUCarea under the concentration-time curve in the interval 0-24 h . calculated by the linear trapezoidal rule; C1= clearance, calculated as dose/AUC, assuming bioavs'lability to be 100% : Cmax = highest observed concentration (measured by enzymo-finked immunosorbent assay) ; Tmax = time to reach Cmax . go . Prothrombin times were only marginally influenced by the tyro dose levels of COP 39393, and platelet counts remained within the normal range (> 150,000/mm3) throughout the study . Three hours after the eighth subcutaneous injection of recombinant hirudin, one volunteer at each dose level had a bleeding time outside the normal values (450 and 630 s, respectively) . Spurious changes in platelet count or bleeding time do not appear to be related to the concentrations of COP 39393 measured by ELISA .
Biologic eitleacy of subcutaneous injections of two dose levels of CGP 39393 every 12 h for 6 consecutive days in kenlthy volunteers . There ware four volunteers for each dose (0.3 and 0 .5 mglkg) of COP 39393, and the subcutaneous injections were given every 12 h for 6 consecutive days . Blood was sampled before and 3 and 12 h after each injection and 16 and 36 h after the last (12th) one . Bleeding time was measured with the Mielke method before the first and 3 h after the last injection .
After the first injection, the mean activated partial thromboplastin time was prolonged to 56.1 s (1 .67 times baseline) and 64.0 s (2 .01 times baseline) for the 0 .3-and 0.5-mg/kg doses, respectively (Table 3 ) . Twelve hours after the first dosing, the mean activated partial thromboplastin time for the two dose levels was 1 .04 and 1 .47 times the mean baseline values, respectively . By 16 and 36 h after the last injection, the mean activated partial thromboplastin time had returned to baseline value for the 0 .3-mg/kg dose . For the 0.5-mg/kg dose level, the mean activated partial thromboplastin time was still slightly prolonged (1 .27 times baseline) after 16 h but had returned to nearly baseline at 36 h .
Median thrombin time (test performed with 6 IU/ml of thrombin) was prolonged to 19. 
Discussion
Single subcutaneous injection of CGP 39393 . The present experience with COP 39393 completes previous reports obtained with natural hirudin in humans (23, 24) . When VERSTRAETE ET a .r .
RECOMBINANT RIRUDIN IN HUMAN VOLUNTEERS 1085 tested in 184 healthy volunteers, the activated partial thromboplastin time was prolonged to almost twice the baseline value 2 h after a single subcutaneous injection of 0 .1 mg/kg of CGP 39393 . The ituersubject coefficient of variation of the weight-adjusted COP 39393 dose level remained within 20% of the mean value, even when COP 39393 was readministered I month apart in these immunocompetent volunteers, suggesting that COP 39393 did not elicit neutralizing antibodies . When four dose levels were tested in four volunteers -rtaining to one center (each volunteer receiving two different doses), the mean activated partial thromboplastin time was maximally prolonged 1 .42, ' . .70, 1 .75 and 2 .05 times the mean baseline values for the 0.1-, 0 .3-, 0 .5-and 0.75-mg/kg subcutaneous doses of COP 39393, respectively .
Onset of effect occurred within the 1st 30 min of administration ; a high concentration was sustained for 4 to 6 h after the dose . Although the duration of the effect of activated partial thromboplastin time was slightly longer at the higher doses, the mean activated partial thromboplastin time Lad returned to approximately baseline values for all four dose levels tested by 24 h after single dosing . The prolongation of activated partial thromboplastin time was related to plasma COP 39393 concentrations, whether measured by the functional or immunologic method, even with the highest concentration confirming in vitro observations in rat plasma (3) . Doubling of the activated partial thromboplastin time is obtained at circa 400 ng of COP 39393/ml of plasma (two-step thrombin chromogenic assay method), which corresponds to approximately 60 nmol/liter . Plasma clearance after subcutaneous injection was between 1 .5 and 1 .7 rnllmin per kg, and apparent elimination half-life was between 2 and 2 .4 h.
Repeated subcutaneous injections of CGP 39393 . When 0 .3 or 0 .5 mg/kg of subcutaneous COP 39393 was injected at 8-h intervals for 3 consecutive days in 16 subjects, the mean activated partial thromboplastin time prolongation, obtained 3 h after dosing, was dose dependent and ranged, respectively, from 1 .67 to 1 .88 times baseline values . The activated partial thromboplastin time changes are reproducible and are again parallel with the concentrations of COP 39393 measured with an immunologic or functional assay . With three times daily subcutaneous administration of CGP 39393 for 3 days, the mean activated partial thromboplastin time and plasma concentrations of CGP 39393 remained elevated at the end of each dosing interval . On the basis of activated partial thromboplastin time prolongation and plasma concentrations of COP 39393, there is no suggestion of cumulative pharmacodynamic and pharmacokinetic effects. Values returned to baseline 16 h after the eighth subcutaneous injection, irrespective of the dose level . When the same two dose levels were administered twice daily, the mean activated partial thromboplastin time obtained 3 h after dosing was dose dependent and ranged from 1 .5 to 2 .5 times baseline . The activated partial thromboplastin time values for the 6-day administration of two dose levels of subcutaneous COP 39393 administered every 12 hours are reproducible and parallel with the changes in the plaima concentration of Table 3 . Plasma Concentration and Effect of Subcutaneous Injections of CGP 39393 on Activated Partial Thromboplastin Time recombinant hirudin . Although with low and medium doses the activated partial thromboplastin time prolongation strongly correlates with the plasma drug concentration. it increases less than proportionally with higher plasma concontrations or increasing doses, Motiltvring of CGP 393!3, The thrombin time directly reflects the inhibition of thrombin and is sensitive to low concentrations of CGP 39393 . Mean concentrations between 30 and 40 nmollliter of recombinant hirudin (ELISA) were shown to double the thrombin time, whereas the activated partial thromboplastin time doubled by a concentration of 1 .14 nmal/liter . By reason of its effective range and simpfic-AP'[Tactivated partial thromboplastin lime . EUSA = enzyme-(inked immunosorbent assay. JACC Vol . 22, No. 4 October 1993 :1080 ity . activated partial thromboplastin time was chosen to monitor the anticoagulant effect of CGP 39393 . These findings are consistent with those previously reported in animals (21, 22) and in humans exposed to natural hirudin (23 -25) and with in vitro experiments performed with recombinant hirudin (3, 4, 24) .
No clear prolongation of bleeding time was observed at mean peak levels after 0 .3 and 0 .5 mg/kg of recombinant hirudin . This suggests that the effect on primary hemostasis is probably minimal, a finding that may be of considerable importance should hirudin be used in the postoperative period . Safety and tolerability in volunteers. Tolerability and safety measurements (physical examination, hemodynamic variables, electrocardiogram, routine clinical chemistry and hematologic values) were not influenced by administration of repeated sulr'cutaneous doses of recombinant hirudin . The activated partial thromboplastin time lest seems to be well suited to monitor the anticoagulant effect because the dose effect is linear up to 0 .5 mg/kg of CGP 39393 . The prolongation of activated partial thromboplastin time after subcutaneous injection of CGP 39393 shows a plateau lasting for 3 h . This is consistent with the slow but nearly complete (85%) absorption from the site of injection reported by Bichler et al . (24) .
Heparin and hirudin are potent inhibitors of thrombin, the central enzyme in thrombosis ; hirudin, however, is a much more selective thrombin inhibitor . There are several features in favor of hirudin as an antithrombotic drug . In contrast to heparin . hirudin is not inactivated by platelet factor 4, histioine-rich glycoprotein or vitronectin, all proteins whose levels are increased in some disorders, which can cause hepudn resistance . Hirudin has no direct effect on platelets and undothelial cells, whereas heparin does, and this may contribute to the risk of bleeding and to heparin-induced thrombocytopenia . Thrombin bound to fibrin or endothelium is inactivated by hirudin but not by heparin ; hirudin is, moreover, independent of antithrombin 111 . Hirudin may thus be a better antithrombotic agent than heparin . Despite the fact that the polypeptide hirudin comes from nonhuman sources, it has the theoretic potential to be allergenic in humans . Local immune reactions to subcutaneous administration of recombinant CGP 39393 in 182 male or female volunteers were not observed (15) . The clinical pharmacology of intravenous bolus injections or infusions of CGP 39393 in healthy volunteers is being reported (26) .
Future directions. The results of this study in healthy volunteers form a reasonable basis for further studies to determine the optimal doses for the prevention of venous and arterial thrombosis in high risk patients . Studies are currently underway comparing recombinant hirudin with standard heparin in the prevention of venous thrombosis after hip surgery (27) . Because coronary reocclusion after thrombolysis is still a problem, notwithstanding concomitant administration of aspirin and intravenous heparin, hirudin is being investigated to prevent early reocclusion and recurrent myocardial infarction (28) . Because hirudin, in contrast to heparin, inhibits thrombin bound to subendothelial extracellular matrix and fibrin remnants, it is logical to explore the effectiveness of hirudin in preventing reocclusion after percutaneous coronary angioplasty (29) .
